What is Evonetix?
Evonetix is pioneering a novel approach to gene synthesis technology aimed at enhancing access to high-quality, gene-length DNA. Their innovative solutions are designed to empower researchers in various fields, including healthcare, agriculture, and manufacturing, by providing unprecedented speed and scale in gene synthesis. The company focuses on addressing critical global challenges through engineering biology, facilitating advancements in personalized medicine and other therapeutic areas. By establishing a gene foundry in every lab, Evonetix aims to accelerate the potential of engineering biology and drive significant innovations.
How much funding has Evonetix raised?
Evonetix has raised a total of $66.3M across 2 funding rounds:
Series A
$12.3M
Series B
$54M
Series A (2018): $12.3M with participation from DCVC Management, Draper Esprit, Providence Investment Advisors, and Morningside Group
Series B (2023): $54M led by Providence Investment Company, Morningside Group, Draper Esprit, Data Collective, Foresite Capital, Cambridge Consultants Ltd, Civilization Ventures, and Rising Tide Fund
Key Investors in Evonetix
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology, employing a data science-driven investment approach.
Draper Esprit
Draper Esprit, founded in 2006 and headquartered in London, UK, is a venture capital firm, with offices in London, Cambridge, and Dublin. Investing in high-growth technology companies with global ambitions.
Data Collective
Data Collective is a startup non-profit. We build and support technology to help people find, understand, and share data, advancing the knowledge and education of citizens everywhere. We started Data Collective because it's way too hard to get simple numerical facts about the world.
What's next for Evonetix?
With this major strategic investment, Evonetix is poised to accelerate its mission of establishing a gene foundry in every lab. The company's focus on engineering biology and its potential to drive advancements in personalized medicine and other therapeutic areas are key growth drivers. This latest round of financing will likely be instrumental in scaling operations, expanding research and development capabilities, and further solidifying its market position in the rapidly evolving biotechnology sector. The strategic nature of this capital infusion suggests a focus on market penetration and the development of next-generation gene synthesis platforms.
See full Evonetix company page
